He M, Li J‐J, Zuo W‐J, et al. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant. Cancer Med. 2019;8:6212--6220. 10.1002/cam4.2453

Min He, Jun‐Jie Li, and Wen‐Jia Zuo are contributed equally to this work

**Funding information**

This study was supported by the National Natural Science Foundation of China (81802638) and the Shanghai Committee of Science and Technology Funds (18ZR1407500).

1. INTRODUCTION {#cam42453-sec-0005}
===============

More than 70% of patients with metastatic breast cancer (MBC) present with hormone receptor‐positive disease.[1](#cam42453-bib-0001){ref-type="ref"} Endocrine therapy is the recommended initial treatment for hormone receptor‐positive metastatic disease in the current guidelines, even with visceral metastases.[2](#cam42453-bib-0002){ref-type="ref"} Prospective trials have shown that endocrine therapy, such as fulvestrant with or without a CDK 4/6 inhibitor, may substantially improve progression‐free survival (PFS) with good patient tolerance.[3](#cam42453-bib-0003){ref-type="ref"}, [4](#cam42453-bib-0004){ref-type="ref"}, [5](#cam42453-bib-0005){ref-type="ref"}, [6](#cam42453-bib-0006){ref-type="ref"}

Fulvestrant, a 17β‐estradiol analog, is an antiestrogen that suppresses estrogen signaling by binding to the estrogen receptor (ER) and inducing its degradation; it has antagonistic activity against estrogen but no agonistic effects on estrogen.[7](#cam42453-bib-0007){ref-type="ref"} Fulvestrant 500 mg was approved as the standard dose for hormone receptor‐positive MBC patients after the CONFIRM study, and the subsequent China‐CONFIRM study found that fulvestrant 500 mg had greater efficacy than fulvestrant 250 mg in patients who experienced disease recurrence or progression after previous endocrine therapy.[8](#cam42453-bib-0008){ref-type="ref"}, [9](#cam42453-bib-0009){ref-type="ref"} The FIRST and FALCON trials further demonstrated the superior efficacy of fulvestrant 500 mg compared to anastrozole in the first‐line setting for hormone receptor‐positive MBC patients.[3](#cam42453-bib-0003){ref-type="ref"}, [10](#cam42453-bib-0010){ref-type="ref"}

The above trials showed that fulvestrant 500 mg was associated with improved efficacy as both a first‐ and later‐line treatment. However, PFS ranged from a few months with a very aggressive course of the disease to several years without major limitations on the quality of life. These findings underscore the importance of defining biological or clinical prognostic factors to develop individualized treatment strategies.

Patients with visceral metastases are often considered less likely to respond to hormonal therapy than those with nonvisceral metastases. In the FALCON study, the median PFS in patients with and without visceral disease was 13.8 months and 22.3 months, respectively, after first‐line treatment with fulvestrant.[2](#cam42453-bib-0002){ref-type="ref"}, [3](#cam42453-bib-0003){ref-type="ref"} Heterogeneity exists among visceral metastases, and to the best of our knowledge, few studies have evaluated differences in the efficacy of endocrine treatment according to the site of visceral metastasis.[11](#cam42453-bib-0011){ref-type="ref"} The lungs are one of the most common visceral metastatic sites; however, it is still unknown whether the sensitivity of patients with lung metastases to endocrine therapy differs from that of those with other visceral metastatic sites. The current article describes a retrospective analysis of patients treated with fulvestrant 500 mg to determine whether patients with visceral metastases (i.e., metastases to the liver and/or lungs) respond differently to treatment and to identify prognostic factors associated with improved PFS with fulvestrant treatment.

2. PATIENTS AND METHODS {#cam42453-sec-0006}
=======================

2.1. Study design and patients {#cam42453-sec-0007}
------------------------------

In this retrospective study, 505 hormone receptor‐positive MBC patients treated with fulvestrant between July 2011 and October 2017 at the Fudan University Shanghai Cancer Center (FUSCC) were enrolled. This study was approved by an independent ethics committee at the FUSCC. All patients provided written informed consent. Clinical data were retrospectively collected from the electronic medical records system.

Eligible patients were women with histologically confirmed ER‐positive and/or progesterone receptor (PgR)‐positive advanced/recurrent breast cancer. Key exclusion criteria were the presence of human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (defined as an immunohistochemical staining score of 3+ or a positive fluorescence in situ hybridization result), treatment with fulvestrant 250 mg, and treatment with fulvestrant combined with other drugs, such as capecitabine, everolimus or an aromatase inhibitor (AI).

The initial site of relapse was established at baseline. Visceral metastasis was defined by baseline disease at any of the following sites: lungs, liver, pleura, brain, ovaries, pleural effusion, adrenal glands, peritoneum, esophagus or pancreas. Patients with lung or liver metastases were further categorized into three subgroups based on their sites of metastasis: lung^w/o\ liver^ metastases (lung metastasis without liver involvement); liver^w/o\ lung^ metastases (liver metastases without lung involvement); and both lung and liver metastases.

2.2. Treatment {#cam42453-sec-0008}
--------------

Fulvestrant was administered intramuscularly in a loading‐dose regimen: 500 mg on days 0, 14, and 28 and once every 28 days thereafter.

2.3. Tolerability and safety {#cam42453-sec-0009}
----------------------------

Adverse events (AEs) were determined retrospectively based on medical records. Generally, fulvestrant was well tolerated in all patients. The most frequently reported AEs were hot flashes, nausea, pain, headaches, vasodilatation, pharyngitis, bone pain, and vomiting. None of these events were sufficiently serious to terminate treatment.

2.4. Statistical analysis {#cam42453-sec-0010}
-------------------------

The primary endpoint of the study was PFS, defined as the time from the start of fulvestrant treatment to objective disease progression (progression of existing disease, appearance of new lesions of disease, or death from any cause). Subjects who had not progressed at the time of the analysis were censored using the last assessment date.

A subgroup analysis of the PFS data was conducted with the following covariates: menopausal status, disease‐free interval (DFI), PgR status, bone‐only metastasis, endocrine treatment‐naïve disease, metastatic sites, prior endocrine therapy for MBC, prior chemotherapy for metastatic disease, and level of responsiveness to endocrine therapy before fulvestrant treatment (primary resistance vs. secondary resistance). Primary resistance to endocrine therapy was defined as recurrence occurring during the first 2 years of adjuvant endocrine therapy or disease progression within the first 6 months of first‐line endocrine therapy for advanced disease. Secondary resistance to endocrine therapy was defined as recurrence occurring after the first 2 years of adjuvant endocrine therapy or disease progression after the first 6 months of endocrine therapy for advanced disease.

Kaplan‐Meier plots were produced for the survival endpoints, and the median PFS was calculated. Univariate logistic regression models followed by multivariable logistic regression models were used to identify factors contributing to prolonged PFS with treatment with fulvestrant 500 mg. Hazard ratios (HRs) were obtained using the Cox proportional hazards regression models, with HR \> 1 reflecting a shortened PFS. Two‐sided *P* values \<.05 were considered statistically significant. All statistical analyses were carried out using SPSS version 21.0 (IBM SPSS Statistics).

3. RESULTS {#cam42453-sec-0011}
==========

3.1. Patient and disease characteristics {#cam42453-sec-0012}
----------------------------------------

In total, 505 patients were enrolled. After excluding 107 ineligible patients, 398 patients were analyzed (Figure [1](#cam42453-fig-0001){ref-type="fig"}). The patients' baseline and disease characteristics are summarized in Table [1](#cam42453-tbl-0001){ref-type="table"}. The median age of the patients at the start of fulvestrant treatment was 58 (range, 30‐86) years. The most common site of metastasis was bone (62.1%). Baseline visceral metastases were present in 233 patients (58.5%), and lung metastases were observed more commonly than liver metastases (179 and 92 patients, respectively). We observed lung^w/o\ liver^ metastases in 138 patients, liver^w/o\ lung^ metastases in 51 patients and both lung and liver metastases in 41 patients. The three remaining patients presented with brain metastases accompanied by soft tissue metastases and had undergone local brain radiotherapy; there was no clinical evidence of disease progression at the time of enrollment. The majority of patients with pleural metastases also presented with lung metastases (21 out of 31).

![CONSORT diagram. \*Fulvestrant was approved by China Food and Drug Administration in March 2011. HER2, human epidermal growth factor receptor 2](CAM4-8-6212-g001){#cam42453-fig-0001}

###### 

Baseline patient demographics and disease characteristics

  Characteristics                                                n = 398      \%
  -------------------------------------------------------------- ------------ ------
  Median age, years                                              58 (30‐86)    
  Menopausal status                                                           
  Premenopause[a](#cam42453-note-0004){ref-type="fn"}            84           21.1
  Postmenopause                                                  314          78.9
  Disease‐free interval[b](#cam42453-note-0005){ref-type="fn"}                
  \>5 years                                                      181          43.0
  ≤5 years                                                       171          45.5
  ER status                                                                   
  Positive                                                       393          98.7
  Negative                                                       5            1.3
  PgR status                                                                  
  Positive                                                       285          71.6
  Negative                                                       95           23.9
  Unknown                                                        18           4.5
  Metastatic sites                                                            
  Nonvisceral                                                    165          41.5
  Bone                                                           247          62.1
  Bone only                                                      61           15.3
  Visceral disease                                               233          58.5
  Any lung                                                       179          45.0
  Any liver                                                      92           23.1
  Lung^w/o\ liver^                                               138          34.7
  Liver^w/o\ lung^                                               51           12.8
  Lung + liver                                                   41           10.3
  Pleural                                                        31           7.8
  Brain[c](#cam42453-note-0006){ref-type="fn"}                   12           3.0
  Ovary                                                          4            1.0
  Other[d](#cam42453-note-0007){ref-type="fn"}                   9            2.3
  No. of disease sites                                                        
  1                                                              122          30.6
  ≥2                                                             276          69.4
  De novo metastatic disease                                     46           11.6
  Adjuvant ET                                                                 
  Antiestrogen ± LH‐RH analog                                    172          43.2
  Aromatase inhibitor ± LH‐RH analog                             102          25.6
  Antiestrogen followed by aromatase inhibitor                   13           3.3
  None                                                           40           10.0
  Unknown                                                        24           6.0
  Prior ET for metastatic disease                                             
  No                                                             145          36.4
  Yes                                                            253          63.6
  Prior ET type for metastatic disease                                        
  Antiestrogen ± LH‐RH analog                                    45           11.3
  Aromatase inhibitor ± LH‐RH analog                             238          59.8
  Everolimus                                                     7            1.8
  Prior sensitivity to ET                                                     
  Primary resistance                                             71           17.8
  Secondary resistance                                           295          74.1
  Prior chemotherapy for metastatic disease                                   
  No                                                             203          51.0
  Yes                                                            195          49.0
  Treatment immediately preceding fulvestrant                                 
  None                                                           32           8.0
  Chemotherapy                                                   102          25.6
  Antiestrogen ± LH‐RH analog                                    45           11.3
  Aromatase inhibitor ± LH‐RH analog                             211          53.0
  Everolimus                                                     4            1
  Other                                                          4            1

Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; LH‐RH, luteinizing; ET, endocrine therapy; hormone‐releasing hormone; Lung^w/o\ liver^, lung metastasis without liver involvement; Liver^w/o\ lung^, liver metastasis without lung involvement.

For premenopausal women, fulvestrant was given upon the administration of LH‐RH.

Patients with stage IV breast cancer at initial diagnosis were excluded (n = 46).

Patients with baseline brain metastases all received local brain radiotherapy, and there was no clinical evidence of disease progression at the time of fulvestrant administration.

Includes patients with baseline disease site of adrenal glands (n = 4), peritoneum (n = 3), esophagus (n = 1) and pancreas (n = 1).
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Thirty‐two patients (8.0%) were completely endocrine therapy naïve, while 145 patients (36.4%) had not received previous endocrine treatment for metastatic disease. Of those who had received previous endocrine treatment for metastatic disease, the majority (238 out of 253) had been exposed to an AI. The last endocrine therapy prior to fulvestrant treatment was an AI for 211 patients (53.0%) and an antiestrogen for 45 patients (11.3%). In addition, 195 (49.0%) patients had undergone chemotherapy for metastatic disease prior to treatment with fulvestrant.

3.2. Efficacy {#cam42453-sec-0013}
-------------

The median follow‐up duration was 26 months. At the time of the analysis, despite immature survival data, 253 patients (63.6%) had experienced disease progression. The overall median PFS was 6.8 months. Significantly longer PFS was observed in patients with nonvisceral disease than in patients with visceral disease (HR 1.33, 95% CI 1.03‐1.72, *P* = .029), with a median PFS of 9.2 months and 5.6 months, respectively. Meanwhile, patients with liver metastases (N = 92) experienced significantly worse PFS than those without liver involvement (N = 306) (3.7 vs. 9.2 months, *P* \< .001; HR 2.17 95% CI 1.65‐2.85, *P* \< .001) (Figure [2](#cam42453-fig-0002){ref-type="fig"}A). Furthermore, similar PFS was observed in patients with nonvisceral disease and those with lung^w/o\ liver^ metastases disease (9.2 vs. 9.6 months, *P* = .86).

![Kaplan‐Meier estimates of progression‐free survival in different subgroups. (A) Patients with or without liver metastases and (B) patients with visceral metastases divided into three subgroups based on metastatic sites. Progression‐free survival in the three subgroups after fulvestrant as first‐line therapy (C) and later‐line therapy (D). Lung^w/o\ liver^, lung metastasis without liver involvement; Liver^w/o\ lung^, liver metastasis without lung involvement; HR: hazard ratios](CAM4-8-6212-g002){#cam42453-fig-0002}

The basic characteristics and prior treatments were balanced among the three subgroups (Table [2](#cam42453-tbl-0002){ref-type="table"}). Kaplan‐Meier curves revealed significantly improved PFS in patients with lung^w/o\ liver^ metastases compared to that in patients with liver^w/o\ lung^ metastases or both lung and liver metastases (liver^w/o\ lung^ metastases compared to lung^w/o\ liver^ metastases: HR 1.70, 95% CI 1.15‐2.51, *P* = .008; both lung and liver metastases compared to lung^w/o\ liver^ metastases: HR 2.85, 95% CI 1.93‐4.22, *P* \< .001). The median PFS in patients with lung^w/o\ liver^ metastases, patients with liver^w/o\ lung^ metastases, and patients with both lung and liver metastases was 9.6, 3.9 and 3.2 months, respectively (Figure [2](#cam42453-fig-0002){ref-type="fig"}B). It is noteworthy that PFS was significantly longer in patients with only lung metastases than in patients with both liver and lung metastases (9.6 vs. 3.2 months, *P* \< .001). However, similar PFS was observed in patients with only liver metastases and patients with both lung and liver metastases (3.9 vs. 3.2 months, *P* = .367).

###### 

Baseline covariates and subgroups by different sites of visceral metastasis

+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Characteristics                           | Lung^w/o\ liver^ metastasis | Liver^w/o\ lung^ metastasis | Lung and liver metastasis |      |            |       |
|                                           |                             |                             |                           |      |            |       |
|                                           | (n = 138)                   | (n = 51)                    | (n = 41)                  |      |            |       |
+===========================================+=============================+=============================+===========================+======+============+=======+
| Median age, years                         | 55 (31‐85)                  |                             | 57 (30‐85)                |      | 57 (31‐79) |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Menopausal status                         |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Premenopausal                             | 23                          | 16.7                        | 10                        | 19.6 | 10         | 24.4  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Postmenopausal                            | 115                         | 83.3                        | 41                        | 80.4 | 31         | 75.6  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Disease‐free interval                     |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| ≤5 years                                  | 50                          | 36.2                        | 26                        | 51.0 | 17         | 41.5  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| \>5 years                                 | 77                          | 55.8                        | 19                        | 37.3 | 22         | 53.7  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| ER status                                 |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Positive                                  | 137                         | 99.3                        | 49                        | 96.1 | 41         | 100.0 |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Negative                                  | 1                           | 0.7                         | 2                         | 3.9  | 0          | 0.0   |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| PgR status                                |                             |                             |                           | 0.0  |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Positive                                  | 97                          | 70.3                        | 38                        | 74.5 | 27         | 65.9  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Negative                                  | 34                          | 24.6                        | 11                        | 21.6 | 13         | 31.7  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Unknown                                   | 7                           | 5.1                         | 2                         | 3.9  | 1          | 2.4   |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| No. of disease sites                      |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| 1                                         | 25                          | 18.1                        | 10                        | 19.6 | 0          | 0.0   |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| ≥2                                        | 113                         | 81.9                        | 41                        | 80.4 | 41         | 100.0 |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Other metastatic sites                    |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Bone                                      | 70                          | 50.7                        | 31                        | 60.7 | 22         | 53.6  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Pleura                                    | 21                          | 15.2                        | 3                         | 5.8  | 4          | 9.7   |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Brain                                     | 6                           | 4.3                         | 1                         | 1.9  | 2          | 4.8   |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Soft tissue                               | 69                          | 50.0                        | 20                        | 39.2 | 24         | 58.5  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| De novo metastatic disease                | 10                          | 7.2                         | 6                         | 11.8 | 2          | 4.9   |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Prior ET for metastatic disease           |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| No                                        | 46                          | 33.3                        | 14                        | 27.5 | 11         | 26.8  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Yes                                       | 92                          | 66.7                        | 37                        | 72.5 | 30         | 73.2  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Prior sensitivity to ET                   |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Primary resistance                        | 26                          | 18.8                        | 19                        | 37.3 | 10         | 24.4  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Secondary resistance                      | 102                         | 73.9                        | 29                        | 56.9 | 29         | 70.7  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Prior chemotherapy for metastatic disease |                             |                             |                           |      |            |       |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| No                                        | 68                          | 49.3                        | 14                        | 27.5 | 9          | 22.0  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+
| Yes                                       | 70                          | 50.7                        | 37                        | 72.5 | 32         | 78.0  |
+-------------------------------------------+-----------------------------+-----------------------------+---------------------------+------+------------+-------+

Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; ET, endocrine therapy; Lung^w/o\ liver^ metastasis, lung metastasis without liver involvement; Liver^w/o\ lung^ metastasis, liver metastasis without lung involvement.
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On this basis, we further evaluated the efficacy of first‐ and later‐line treatment with fulvestrant in the three subgroups (Figure [2](#cam42453-fig-0002){ref-type="fig"}C,D). For patients receiving first‐line fulvestrant treatment, the HRs were as follows: liver^w/o\ lung^ metastases compared to lung^w/o\ liver^ metastases, HR 1.96, 95% CI 0.91‐4.24, *P* = .086; and both lung and liver metastases compared to lung^w/o\ liver^ metastases, HR 10.4, 95% CI 4.4‐24.6, *P* \< .001. For patients receiving later‐line fulvestrant treatment, the HRs were as follows: liver^w/o\ lung^ metastases compared to lung^w/o\ liver^ metastases, HR 1.60, 95% CI 1.01‐2.54, *P* = .044; and both lung and liver metastases compared to lung^w/o\ liver^ metastases, HR 1.92, 95% CI 1.21‐3.03, *P* = .005.

3.3. Prognostic factors and their associations with the outcome {#cam42453-sec-0014}
---------------------------------------------------------------

The results of the PFS analyses using Cox proportional hazard regression are shown in Table [3](#cam42453-tbl-0003){ref-type="table"}. DFI, bone‐only metastases, liver metastases, being endocrine therapy naïve, prior endocrine therapy for MBC and prior chemotherapy for MBC were significantly related to PFS (all *P* \< .05). When we further corrected for these factors in the multivariate analysis, the results revealed that patients who had not received previous chemotherapy for advanced disease (HR 1.93, 95% CI 1.32‐2.82, *P* = .001), patients without liver metastases (HR 1.51, 95% CI 1.05‐2.18, *P* = .027) and patients with a DFI greater than 5 years (HR 1.42, 95% CI 1.01‐1.99, *P* = .043) experienced significantly longer PFS than their counterparts.

###### 

Univariate and multivariate analysis of progression‐free survival by prespecified stratification factors

  Variables                                   n     Univariate   Multivariate                                   
  ------------------------------------------- ----- ------------ -------------- ------------ ------ ----------- ----------
  Menopausal status                                                                                              
  Premenopausal                               84    11.0         6.4‐15.7                    --     --          --
  Postmenopausal                              314   5.9          4.7‐7.1        .052         --     --          --
  Disease‐free interval                                                                                          
  \>5 years                                   181   8.6          5.8‐11.5                    1                   
  ≤5 years                                    171   4.8          3.6‐6.0        **.003**     1.42   1.01‐1.99   **.043**
  PgR status                                                                                                     
  Positive                                    285   6.9          5.3‐8.6                     --     --          --
  Negative + UK                               113   5.5          4.6‐6.3        .107         --     --          --
  Bone‐only metastasis                                                                                           
  Yes                                         61    10.9         2.7‐19.0                    1                   
  No                                          337   5.8          4.8‐6.8        **.002**     1.69   0.91‐2.80   .06
  Metastatic sites                                                                                               
  Nonvisceral                                 165   9.2          6.7‐11.7                    1                   
  Lung^w/o\ liver^                            138   9.6          5.3‐13.9       .860         --     --          --
  Liver                                       92    3.7          2.9‐4.5        **\<.001**   1.51   1.05‐2.18   **.027**
  ET naïve                                                                                                       
  Yes                                         32    26.8         NE‐59.3                     1                   
  No                                          366   6.0          4.9‐7.2        **.01**      2.12   0.99‐4.54   .052
  Prior ET for metastatic disease                                                                                
  0                                           145   11.0         5.5‐16.6                    1                   
  ≥1                                          253   5.6          4.9‐6.3        **.002**     0.91   0.62‐1.34   .645
  Sensitivity to prior ET                                                                                        
  Primary resistance                          71    4.0          2.9‐5.0                     --     --          --
  Secondary resistance                        295   7.0          5.6‐8.3        .05          --     --          --
  Prior chemotherapy for metastatic disease                                                                      
  0                                           203   9.9          6.5‐13.2                    1                   
  ≥1                                          195   4.7          3.9‐5.5        **\<.001**   1.93   1.32‐2.82   **.001**

Abbreviations: PgR, progesterone receptor; UK, unknown; HR, hazard ratio; 95% CI, 95% confidence interval; ET, endocrine therapy; NE, not estimable; Lung^w/o\ liver^, lung metastasis without liver involvement.

Median PFS in months.

*P* \< .05 was considered significant; significant values are presented in bold.
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4. DISCUSSION {#cam42453-sec-0015}
=============

In the current study analyzing MBC patients treated with fulvestrant 500 mg, PFS was similar in patients with lung^w/o\ liver^ metastases and those with nonvisceral metastases and much longer than that in patients with liver^w/o\ lung^ metastases or both lung and liver metastases.

Our analysis included only patients treated with fulvestrant 500 mg and excluded those treated with fulvestrant 250 mg or other medications concomitantly. Previously, the phase II study FINDER2 was among the first to demonstrate the superior therapeutic efficacy of fulvestrant 500 mg compared to that of fulvestrant 250 mg,[12](#cam42453-bib-0012){ref-type="ref"} and the phase III prospective trial CONFIRM further showed that fulvestrant 500 mg was superior to fulvestrant 250 mg, as indicated by a significant increase in PFS and a corresponding clinically meaningful improvement in benefit vs. risk.[13](#cam42453-bib-0013){ref-type="ref"} Hence, only patients treated with the currently approved and now standard dose of fulvestrant 500 mg were analyzed in this study.

The randomized phase III FALCON trial proved fulvestrant 500 mg to be superior to anastrozole in treating postmenopausal hormone receptor‐positive MBC patients, yet its subgroup analysis did not reveal superior therapeutic efficacy for fulvestrant in the treatment of visceral disease.[3](#cam42453-bib-0003){ref-type="ref"} One explanation may be that the lack of a distinction among visceral sites in the visceral disease subgroup and their varying prognostic values resulted in an underestimation of the efficacy of fulvestrant. Our study demonstrates the varying prognostic values of different metastatic sites and indicates that patients with liver^w/o\ lung^ metastases and those with lung^w/o\ liver^ metastases did not benefit equally from fulvestrant treatment. Our results are in accordance with a recently published meta‐analysis by Robertson et al,[14](#cam42453-bib-0014){ref-type="ref"} which showed that patients with advanced hormone receptor + breast cancer with nonvisceral metastasis and visceral non‐liver metastasis had significantly better outcomes on endocrine therapy than patients with visceral liver metastasis.

To the best of our knowledge, this is the first study to differentiate between visceral metastatic sites and reveal a significant correlation between the visceral organs involved and the patient\'s prognosis after endocrine treatment. We hypothesize that there are distinct differences in the prognoses of patients with different sites of metastasis. This hypothesis is supported by a prognostic score for MBC published by Regierer et al,[11](#cam42453-bib-0011){ref-type="ref"} which identified the site of metastasis as one of the significant independent prognostic factors of overall survival. Their prognostic score assigned varying points to different metastatic sites; the lungs, bone, soft tissue and effusion were assigned 4 points each, whereas the liver was assigned 7 points, the brain 8 points and the bone marrow 10 points. We can infer from the point values that lung metastases had a relatively small adverse effect on patient prognosis. In addition, univariate analysis of pooled data from the MONARCH 2 and 3 studies did not identify lung metastasis as a prognostic factor, while liver metastasis was found to be a significant prognostic factor, and a significant difference in the median PFS was observed between patients with and without baseline liver metastasis after fulvestrant treatment.[15](#cam42453-bib-0015){ref-type="ref"} Similarly, a retrospective study from Japan regarding the efficacy of fulvestrant against MBC also found the presence of liver metastasis to be significantly correlated with poorer PFS.[16](#cam42453-bib-0016){ref-type="ref"}

Aside from the metastatic site, the DFI and prior chemotherapy for metastatic disease were also significant prognostic factors in our study, which is in agreement with the results of a meta‐analysis that reported significantly better time to progression/PFS in patients with a longer time from diagnosis to recurrence after fulvestrant treatment.[17](#cam42453-bib-0017){ref-type="ref"} In clinical practice, patients with visceral metastases are more likely to receive initial chemotherapy[11](#cam42453-bib-0011){ref-type="ref"}; however, ER‐positive MBC patients are more likely to respond to hormonal therapy when it is administered before chemotherapy.[18](#cam42453-bib-0018){ref-type="ref"} Our results reflect a similar conclusion, with patients who had not received prior chemotherapy for MBC exhibiting a significantly longer median PFS than those who had received prior chemotherapy.

Furthermore, univariate analysis revealed that the line of fulvestrant treatment was significantly associated with PFS; however, the same finding was not revealed by multivariate analysis. This may be due in part to our modest sample size and other confounding factors associated with retrospective analyses. The median PFS of patients treated with fulvestrant as a first‐line endocrine therapy was 11.0 months, shorter than that reported in the FIRST and FALCON studies.[3](#cam42453-bib-0003){ref-type="ref"}, [19](#cam42453-bib-0019){ref-type="ref"} One possible explanation is that the majority of patients in our study had previously received adjuvant endocrine therapy, and some had received chemotherapy for metastatic disease before starting fulvestrant.

Inevitably, our study had limitations. First, our study was performed using retrospective datasets rather than prospective cohorts, and sampling biases may have been introduced. Second, while the sample size of our study was substantial, with 58.5% of patients analyzed having visceral metastases and undergoing endocrine therapy, our results are from a single center and should be interpreted with caution.

5. CONCLUSIONS {#cam42453-sec-0016}
==============

The present study investigated the prognostic factors associated with improved PFS after fulvestrant 500 mg treatment in a population of Chinese breast cancer patients. Our results demonstrate that patients with liver metastases respond poorly to fulvestrant; in contrast, the efficacy of fulvestrant treatment in patients with lung^w/o\ liver^ metastases was comparable to that in patients with nonvisceral metastases. Therefore, we suggest that categorizing MBC patients into those with liver and non‐liver metastases may better reflect patient prognosis than the current categorization of patients with visceral and nonvisceral metastases. However, further studies are necessary to determine whether patients with hormone receptor‐positive/HER2‐negative MBC would benefit from being treated differentially according to the site of visceral metastasis, and we await the results of subgroup analyses from prospective, multicenter trials for more supporting evidence.

CONFLICTS OF INTEREST {#cam42453-sec-0017}
=====================

The authors have declared no conflicts of interest.

The authors are grateful to all patients who participated in the study. We acknowledge Qiong Du, Lei Ji, Fu‐Gui Ye, Xiao‐Yan Ma, Pei‐Yang Lin, and Hai‐Yun Zhao for data collection, Wen‐Jia Zuo for critically reviewing the manuscript, Zhong‐Hua Wang and Zhi‐Ming Shao for their leadership and guidance.
